Introduction
============

Diabetes mellitus (DM) is a worldwide health care problem that places a heavy burden on patients and society. Diabetes and other parameters of metabolic disorder are considered risk factors for cardiovascular disease. Diabetic patients exhibit a two- to four-fold increased risk of cardiovascular disease, while endothelial cell dysfunction has a major role in the initiation and progression of vascular complications ([@b1-etm-0-0-8239]). The endothelium is a semipermeable monolayer of spindle-shaped endothelial layers that help maintain vascular homeostasis under physiological conditions ([@b2-etm-0-0-8239]). In diabetes, endothelial function is compromised, including reduced plasma nitric oxide, increased generation of reactive oxygen species, increased leukocyte infiltration and subsequent inflammation load ([@b3-etm-0-0-8239],[@b4-etm-0-0-8239]). Therefore, ameliorating endothelial dysfunction is a major focus for the prevention and treatment of diabetic vascular complications. Compared with type 1 DM, which is characterized by the autoimmune destruction of β-cells, type 2 DM accounts for 90--95% of all cases of diabetes ([@b5-etm-0-0-8239]). Type 2 DM is insulin-independent and usually characterized by a partial reduction of insulin secretion and insulin resistance ([@b6-etm-0-0-8239]).

Endothelial precursor cells (EPCs) are a group of cells with the inherent capacity to differentiate into mature cells ([@b7-etm-0-0-8239]). Asahara *et al* ([@b8-etm-0-0-8239]) reported on the isolation of these CD34-positive mononuclear cells from human peripheral blood. EPCs have been indicated to integrate into the capillary-vessel endothelium of rodent hindlimbs induced by ligation of the artery ([@b9-etm-0-0-8239]). Previous studies also revealed the potency of EPCs in the treatment of endothelial dysfunction induced by diabetes ([@b10-etm-0-0-8239],[@b11-etm-0-0-8239]). However, compared with those in healthy subjects, EPC counts were lower, and the function was also disturbed in patients with either type of DM ([@b12-etm-0-0-8239]--[@b14-etm-0-0-8239]). The development of strategies to improve the counts and activity of EPCs in patients with DM is a major focus in the field of autologous cell therapy. As EPCs from patients with diabetes exhibit different behaviors compared with those from healthy subjects, several different approaches have been investigated to restore their dysregulation and dysfunction by targeting specific sites ([@b15-etm-0-0-8239]--[@b18-etm-0-0-8239]).

In the present study, differentially expressed genes (DEGs) in EPCs from patients with type 2 DM vs. healthy subjects were identified. These DEGs were then subjected to gene ontology (GO) and pathway enrichment analyses. A protein-protein interaction (PPI) network was then constructed and visualized, and hub genes were identified by molecular complex detection (MCODE). The top 9 hub genes were subsequently verified by reverse transcription-quantitative (RT-q)PCR in an independent sample set originating from our study center. To further explore the genes that may be associated with the hub genes, a weighted gene co-expression network analysis (WGCNA) was performed to determine a relevant module that incorporates the hub genes, especially interleukin 8 (IL8) and CXC chemokine ligand 1 (CXCL1).

Materials and methods
=====================

### Obtainment and pre-processing of microarray data

Gene expression profiles of EPCs from healthy and type 2 diabetic subjects were obtained from the Gene Expression Omnibus database (GEO; [www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)). The accession number was GSE43950, and this dataset included a total of 14 samples: A total of 9 type 2 diabetes late stage EPC samples and 5 healthy late EPC stage samples. The definition of early and late stage EPCs is discussed in a previous study ([@b19-etm-0-0-8239]). Late EPC samples referred to the EPCs appeared aged 2--4 weeks and exhibited a cobblestone-like morphology ([@b8-etm-0-0-8239]). The 9 type 2 diabetes late EPC samples consisted of 5 samples obtained from the type 2 diabetes patients with microvascular complications and 4 samples from the type 2 diabetes patients without clinical microvascular injuries. To identify the DEGs in patients with type 2 diabetes vs. non-diabetic controls, the 9 diabetes samples were analyzed together. The platform used was the Rosetta/Merck Human RSTA Custom Affymetrix 2.0 microarray GPL10379. First, the expression matrix from the GEO database was pre-processed using the robust multi-array analysis method. The probe ID for each gene was then converted to a gene symbol using annotation files obtained from the platform. DEGs were identified by the limma algorithm (<http://www.bioconductor.org/packages/2.9/bioc/html/limma.html>) in R software ([@b20-etm-0-0-8239],[@b21-etm-0-0-8239]). A P-value of \<0.05 and \|log~2~ fold change\|≥1 were used as the cutoff criteria for this analysis.

### Enrichment analysis of DEGs

GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway functional enrichment analyses were performed using the database for annotation, visualization and integrated discovery (DAVID; <http://david.ncifcrf.gov/>) ([@b22-etm-0-0-8239]). P\<0.05 was considered to indicate statistical significance and the GO results were ranked by P-value. The significant terms for biological process (BP), cellular component (CC) and molecular function (MF) were visualized in Cytoscape ([@b23-etm-0-0-8239]). Furthermore, the top 10 GO terms in the categories BP, CC and MF, and the top 10 KEGG pathways were presented in bubble plots generated with ggplot2 (<https://cran.rproject.org/web/packages/ggplot2/index.html>) in R.

### PPI network construction

A PPI network was generated to infer the interactions among proteins. The PPI network was constructed using the Search Tool for the Retrieval of Interacting Genes and proteins (STRING) database (<https://string-db.org/>) ([@b24-etm-0-0-8239]). To explore the regulatory mechanisms, interactions with the highest confidence of a combined score \>0.900 were imported into Cytoscape to construct the PPI network.

### Module selection

To obtain clusters of genes in the PPI network, MCODE was used to identify the modules in the PPI network. The cutoff criteria were 'degree cutoff=2', 'node score cutoff=0.2', 'k-core=2' and 'maximum depth=100'.

### Analysis of hub genes

To obtain a balance between the core genes and to avoid missing any key gene, hub genes were extracted using cytoHubba. A total of 12 topological analyses were provided by the cytoHubba plugin ([@b25-etm-0-0-8239]). In accordance with previous reports, a total of 3 most widely used topological analysis methods, including maximal clique centrality (MCC), maximum neighborhood component (MNC) and density of maximum neighborhood component (DMNC), were used to identify potential hub genes ([@b25-etm-0-0-8239],[@b26-etm-0-0-8239]). The overlapping genes were selected as the hub genes using Venn diagrams.

### Construction of the co-expression network and identification of significant modules

The WGCNA package in R was used to construct a co-expression network ([@b27-etm-0-0-8239]). After calculating the correlation of all pairwise genes by Pearson\'s correlation matrices, the appropriate soft-threshold power β was selected for the construction of modules using the pickSoftThreshold function ranging from 1 to 30. The power of β=16 (scale-free R^2^=0.818) was selected to construct a scale-free network. The topological overlap matrix (TOM) was therefore constructed to measure the network connectivity of each gene, defined as the sum of its adjacency with all other genes for network generation ([@b28-etm-0-0-8239]). The interaction analysis among different co-expression modules was performed using the flashClust function, and the average linkage hierarchical clustering was used with a minimum size of 500 for the gene dendrogram ([@b29-etm-0-0-8239]). The module-trait association was estimated using the correlation between the module eigengene and the phenotype. Gene significance (GS) was defined as the absolute value of the correlation between expression profile and clinical trait. Module membership (MM) was designated as the correlation of the expression profile and each module eigengene ([@b30-etm-0-0-8239]). Genes with higher intramodular connectivity (IC) were thought to have biological significance compared with other genes in the module ([@b31-etm-0-0-8239]). Therefore, the top 10% genes ordered by IC were functionally annotated. Finally, KEGG functional enrichment analysis of pathways in the pink module was performed using the clusterProfiler package ([@b32-etm-0-0-8239]).

### Isolation and cultivation of circulating EPCs

The EPCs used in the present study were obtained from patients diagnosed with type 2 DM or from non-diabetic controls at Sir Run Run Shaw Hospital (Hangzhou, China). Type 2 DM was diagnosed according to the American Diabetes Association criteria ([@b33-etm-0-0-8239]). Inclusion/exclusion criteria for the patients enrolled in the present study were as follows: Age \>50 years, willingness to provide written informed consent, no acute myocardial infarction and no acute stroke. The patients with type 2 DM were diagnosed \>5 years previously. Furthermore, major diabetic complications (diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, lower limb arteriopathy) were recorded according to criteria described previously ([@b34-etm-0-0-8239]). A total of 8 patients were enrolled in the present study between April 2017 and April 2018. EPCs were isolated, cultured and characterized according to methods previously reported ([@b35-etm-0-0-8239]). The study procedure was approved by the Ethics Review Board of Sir Run Run Shaw Hospital, School of Medicine. In brief, peripheral blood mononuclear cells were isolated by density gradient centrifugation. Cells were cultured in Endothelial Basal Medium-2 (Lonza Group, Ltd.) supplemented with corresponding nutrient factors including 10% FBS (Gibco; Thermo Fisher Scientific, Inc.). Non-adherent cells were removed after 4 days of primary culture. The culture was maintained for another 7 days following addition of fresh medium. The purity of the EPCs was verified using tetramethylindocarbocyanine-labelled acetylated low-density lipoprotein (DiLDL) uptake and lectin binding under a laser scanning confocal microscope (data not shown) (Zeiss AG). The third generation of EPCs was selected for the subsequent analysis. Detailed information on these patients is provided in Supplemental [Table SI](#SD1-etm-0-0-8239){ref-type="supplementary-material"}.

### Validation of microarrays by RT-qPCR

To verify the major conclusions drawn from the microarray data, the expression levels of genes encoding for identified hub genes in EPCs from patients were determined. The RNA of EPCs was extracted using TRIzol reagent (CWBIO) and converted into complementary (c)DNA using a PrimeScript RT reagent Kit (Takara Biotechnology, Co. Ltd) according to the manufacturer\'s protocol. Subsequently, qPCR was performed using UltraSYBR Mixture (Low ROX; CWBIO) on the Lightcycler 480 II system (Roche Life Science). For each well, the reaction mixture contained 2 µl cDNA, 0.4 µl forward primer (0.2 µM), 0.4 µl reverse primer (0.2 µM), 7.2 µl RNA-free water and 10 µl 2X UltraSYBR Mix. The reactions were incubated at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. The expression data were normalized to the reference GAPDH. FCs of relative mRNA expression were calculated using the change-in-threshold method (2^−ΔΔCq^) ([@b37-etm-0-0-8239]). The primer sets used for qPCR are listed in [Table I](#tI-etm-0-0-8239){ref-type="table"}.

### Statistical analysis

All experiments were performed at least three times. All results are expressed as the mean ± standard deviation. Statistical analyses were performed using Student\'s t-test with GraphPad Prism 7 software (GraphPad Software, Inc.). P\<0.05 was considered to indicate statistical significance.

Results
=======

### Identification of DEGs and clustering analysis

A total of 970 DEGs were finally screened from the expression profiles and are presented in a volcano plot in [Fig. 1A](#f1-etm-0-0-8239){ref-type="fig"}.

Clustering analysis was then performed using the pheatmap package in R and 970 DEGs were divided into two major clusters ([Fig. 1B](#f1-etm-0-0-8239){ref-type="fig"}). They included 822 upregulated and 148 downregulated genes ([Fig. 1C](#f1-etm-0-0-8239){ref-type="fig"}). The top 10 upregulated and top 10 downregulated DEGs ranked by P-value are presented in [Table II](#tII-etm-0-0-8239){ref-type="table"}.

### Enrichment analysis of DEGs

To explore the GO terms and pathways in which the DEGs were mainly involved, the 970 DEGs were uploaded onto the DAVID website. The most enriched GO terms in the category BP included 'inflammatory response', 'cellular response to lipopolysaccharide', 'innate immune response', 'immune response' and 'lipopolysaccharide-mediated signaling pathway' ([Fig. 2A](#f2-etm-0-0-8239){ref-type="fig"}). In the category CC, the GO terms with the highest enrichment were mainly associated with 'extracellular exosomes', 'plasma membranes', 'lysosomes and cell surface' ([Fig. 2B](#f2-etm-0-0-8239){ref-type="fig"}). As for the category MF, the GO terms with the highest accumulation of DEGs were 'protein binding, receptor activity', 'carbohydrate binding' and 'lipopolysaccharide receptor activity' ([Fig. 2C](#f2-etm-0-0-8239){ref-type="fig"}).

To identify pathways significantly enriched by the DEGs, KEGG pathway analysis was performed. The enrichment analysis of the KEGG pathways demonstrated that DEGs were mainly enriched in the 'NF-κB signaling pathway', 'tumor necrosis factor (TNF) signaling pathway' and 'inflammatory bowel disease' ([Fig. 2D](#f2-etm-0-0-8239){ref-type="fig"}).

### PPI network construction and module analysis

A total of 394 nodes and 1,486 interactional pairs were included in the PPI network ([Fig. 3](#f3-etm-0-0-8239){ref-type="fig"}). Among them, proteins with degrees of ≥20 were visualized in detail. A total of 5 proteins had degrees of interaction of ≥30 \[IL8, 43; ubiquitin conjugating enzyme E2 D1 (UNE2D1), 35; G protein subunit beta 1 (GNB1), 33; E1A binding protein p300 (EP300), 32; Cbl proto-oncogene (CBL), 30\]. In addition, a subnetwork clustering analysis was performed using the MCODE plugin. The top 3 subnet modules were identified ([Fig. 4A-C](#f4-etm-0-0-8239){ref-type="fig"}). Module a (score=20.634) included 42 nodes and 423 interactional pairs ([Fig. 4A](#f4-etm-0-0-8239){ref-type="fig"}). Module b (score=12.000) included 12 nodes and 66 interactional pairs ([Fig. 4B](#f4-etm-0-0-8239){ref-type="fig"}). Module c (score=7.641) included 40 nodes and 149 interactional pairs ([Fig. 4C](#f4-etm-0-0-8239){ref-type="fig"}).

### Hub gene selection

The hub genes were determined by overlapping the top 20 genes obtained using three topological analysis methods, MCC, MNC and DMNC ([Fig. 5A](#f5-etm-0-0-8239){ref-type="fig"}). A total of 9 genes were selected, including 8 upregulated genes and 1 downregulated gene ([Fig. 5B](#f5-etm-0-0-8239){ref-type="fig"}; [Table III](#tIII-etm-0-0-8239){ref-type="table"}).

### Validation of hub genes by RT-qPCR

RT-qPCR was used to validate hub genes obtained in the above analysis. EPCs were isolated from 4 non-diabetic controls and 4 diabetic patients. The detailed information of these patients were presented in [Table S1](#SD1-etm-0-0-8239){ref-type="supplementary-material"}. The patients that met the criteria were included from April 2017 to April 2018. The mRNA expression levels of IL8, formyl peptide receptor 1 (FPR1), CXCL1, GNAI3, FPR2, GNAI2, annexin A1 (ANXA1), GNB1 and lysophosphatidic acid receptor 5 (LPAR5) were determined. Overall, the results were similar to those of the microarray analysis, while the RT-qPCR results indicated greater fold changes than those calculated from the gene array data ([Fig. 6](#f6-etm-0-0-8239){ref-type="fig"}). Of all 9 genes, IL8 and CXCL1 exhibited the most significant changes.

### WGCNA and key module identification

To further explore the roles of chemokines in EPCs under diabetic conditions, WGCNA was used to identify the relevant modules incorporating IL8 and CXCL1. Prior to construction of the co-expression network, the soft-threshold power of 16 was selected to define the adjacency matrix based on the criterion of approximate scale-free topology ([Fig. 7A and B](#f7-etm-0-0-8239){ref-type="fig"}). After determining the soft-threshold, the TOM was built. A total of 9 distinct gene co-expression modules for EPCs were constructed and are presented in different colors ([Fig. 7C](#f7-etm-0-0-8239){ref-type="fig"}). IL8 and CXCL1 are included in the pink module ([Fig. 8A](#f8-etm-0-0-8239){ref-type="fig"}). The values between module membership (MM) and gene significance (GS) in the pink module were presented in [Fig. 8B](#f8-etm-0-0-8239){ref-type="fig"}. Genes with high IC were indicated to be tightly associated with other genes. The top 10% genes in the pink module ordered by IC were mainly enriched in the pathway of IL17 and the chemokine signaling pathway using KEGG pathway analysis ([Fig. 8C](#f8-etm-0-0-8239){ref-type="fig"}).

Discussion
==========

EPCs are a group of multipotent precursor cells that have the capacity to differentiate into blood vessels and blood cells ([@b38-etm-0-0-8239]). However, in previous studies, the number and function of EPCs were indicated to be decreased in patients with type 2 DM ([@b12-etm-0-0-8239],[@b39-etm-0-0-8239]). Thus, identification of DEGs may be beneficial for the elucidation of the pathophysiology of EPCs in patients with diabetes. By analyzing the expression profiles in the dataset GSE43950 downloaded from the GEO database, 970 DEGs were identified, including 822 upregulated and 148 downregulated genes. Subsequent analyses included GO enrichment analysis of DEGs, KEGG pathway analysis, module selection by MCODE and identification of hub genes by cytoHubba. Thereafter, hub genes selected from the PPI network were validated by RT-qPCR and associated modules containing hub genes with the highest FC were investigated. To the best of our knowledge, the present study was the first aiming to determine potential genes associated with EPCs in patients with type 2 DM. The present study provides novel insight into the molecular mechanisms of dysfunctional EPCs in patients with type 2 DM.

Through the use of DAVID, GO enrichment analysis of the 970 DEGs was performed and the most enriched GO terms in the category BP were associated with 'inflammatory response, response to lipopolysaccharide' and 'innate immune response' in patients with type 2 DM. In the category CC, enriched GO terms were mainly associated with 'extracellular exosomes', 'plasma membranes' and 'lysosomes'. In the category MF, GO terms enriched for DEGs in DM groups included 'protein binding' and 'receptor activity'. KEGG pathway analysis indicated that the DEGs of the type 2 DM group were mainly enriched in the 'TNF signaling pathway' and 'NF-κB signaling pathway'. The GO terms 'inflammatory response', 'response to lipopolysaccharide' and 'innate immune response' fit well with concept of an inflammatory phenotype in the EPCs of type 2 DM as described previously ([@b15-etm-0-0-8239]). Indeed, it has been indicated that anti-diabetic drugs that possess the capacity to increase EPC numbers and inhibit premature apoptosis may protect EPCs from injury by DM partly through alleviation of inflammation ([@b40-etm-0-0-8239]). In the category CC, the GO term 'extracellular exosome' was indicated to be of high relevance. Exosomes have been reported to have an important role in the performance of EPCs under certain physiological and pathological conditions ([@b41-etm-0-0-8239]--[@b43-etm-0-0-8239]). It is reasonable to speculate that the decreased number and inhibited function of EPCs may partially be attributed to the altered exosome content of EPCs in patients with type 2 DM. These exosomes may perform multiple biological functions, including angiogenesis and wound healing ([@b43-etm-0-0-8239],[@b44-etm-0-0-8239]). In the category MF, DEGs were mainly enriched in 'protein binding', 'receptor activity' and 'lipopolysaccharide receptor activity'. As for the KEGG pathways, the 'NF-κB signaling pathway' and 'TNF signaling pathway' were enriched in EPCs of patients with type 2 DM. Above all, these results indicated that inflammation may have a major role in the initiation and progression of dysfunction of EPCs in patients with DM, in accordance with previous studies ([@b15-etm-0-0-8239],[@b43-etm-0-0-8239]).

To illustrate the interaction of the DEGs, a PPI network was constructed using the STRING database. The top 3 subnet modules based on the PPI network were then selected by MCODE. GO enrichment analysis of these modules (including subnet modules a, b, and c) revealed that these subnet modules were mainly enriched in the terms inflammation, endocytosis and Golgi vesicle-mediated transport processes. The results of the enrichment analysis in the subnet modules further demonstrated that inflammation may be crucial for the dysfunction of EPCs in patients with type 2 DM.

By overlapping the top 20 genes obtained from the MCC, MNC and DMNC methods, 9 genes were selected (IL8, FPR1, CXCL1, GNAI3, FPR2, GNAI2, ANXA1, GNB1 and LPAR5). Among these genes, IL8 exhibited the most significant difference between the diabetic and control samples. IL8, as a member of the chemokines, has been reported to activate the motile apparatus of neutrophils, inducing the surface adhesion of inflammatory cells ([@b45-etm-0-0-8239]). Monocytes and macrophages are usually considered the principal cellular source of IL8. However, a wide variety of nucleated cells, including EPCs, are potential sources of IL8 ([@b46-etm-0-0-8239]). Previous studies have indicated that in patients with type 2 DM, IL8 is elevated in the plasma compared with that in healthy subjects ([@b47-etm-0-0-8239]). IL8 is considered a canonical angiogenic factor and has a crucial role in the protection of EPCs for attenuating injury and prompting recovery of damaged tissues ([@b48-etm-0-0-8239]--[@b50-etm-0-0-8239]). Consistent with a previous study, the current study indicated that IL8 was significantly higher in the microarrays of EPCs isolated from patients with diabetes ([@b51-etm-0-0-8239]). Furthermore, the results of detecting mRNA expression in EPCs under type 2 DM by *RT-qPCR* were similar. All these results indicated that elevated IL8 may be involved in the dysfunction of EPCs during the long-term injury associated with type 2 DM.

Besides IL8, CXCL1 was also significantly elevated with a similar degree to that of IL8. CXCL1, best known for its chemotactic activity toward neutrophils and monocytes/macrophages, is also a potent angiogenic factor ([@b52-etm-0-0-8239]). Herlea-Pana *et al* ([@b53-etm-0-0-8239]) reported that CXCL1 and its cognate receptor, CXC motif chemokine-receptor-2 (CXCR2), were increased in Reversa mice, an animal model apt to develop plaques when fed an atherosclerosis-inducing western diet. Of note, elevated CXCL1-CXCR2 was indicated to have a protective effect to prevent the progression of plaque formation, while CXCR2 was able to recruit EPCs to the plaques to repair the injured endothelium. Likewise, the chemokine system was indicated to be associated with homing and engraftment of EPCs ([@b54-etm-0-0-8239]). Above all, these results indicated that the chemokine system has an important role in the regulation of EPCs under diabetic conditions.

To further explore the genes that may be associated with IL8 and CXCL1 in the microarray data, WGCNA was performed to determine the relevant module that incorporates IL8 and CXCL1. A total of 9 modules were recognized by dynamic tree cut, of which the pink module contained IL8 and CXCL1. Most genes in this module were enriched in the TNF signaling pathway, the chemokine signaling pathway and the NOD-like receptor signaling pathway. These pathways fit well with the concept of an inflammatory and immune system disorder in type 2 DM ([@b55-etm-0-0-8239],[@b56-etm-0-0-8239]).

The microarray data analyzed in the present study were deposited in the GEO as the dataset GSE43950. By analyzing these microarray data, the present study aimed to identify candidate genes that may be helpful for understanding the roles of EPC dysfunction under type 2 DM conditions and the associated mechanisms. Furthermore, to minimize the bias in the original expression profiles and to better understand the functional terms and pathways of the DEGs in the EPCs influenced by type 2 DM, the array data were analyzed in three steps. First, DEGs between healthy subjects and diabetes patients were determined from the microarrays using the classical bioinformatics analysis tool, limma. Subsequent enrichment analysis was performed by DAVID. Hub genes and associated modules based on PPI network were selected using cytohubba in Cytoscape. Thereafter, the predicted hub genes were validated by RT-qPCR of EPCs isolated from patients at Sir Run Run Shaw Hospital (Hangzhou, China). IL8 and CXCL1 were found to exhibit the greatest variation in the EPCs of patients. To identify the genes that were co-expressed with IL8 and CXCL1, WGCNA, which is an algorithm recently wide used in microarray data analyses to identify the modules with similar expression patterns, was applied in the current study ([@b57-etm-0-0-8239]). After selecting the appropriate soft-threshold power β, the pink module was indicated to incorporate IL8 and CXCL1.

The present results indicated that inflammation may be an important mechanism underlying the difference in function and number of EPCs isolated from healthy individuals and diabetic patients. EPCs have long been regarded as a potential therapy to accelerate re-endothelialization of impaired vessels. Elevated IL8 expression is also thought to be involved in the repair progress ([@b18-etm-0-0-8239]). Compared to the successful preclinical results, the results of clinical trials on the efficacy parameters are conflicting ([@b58-etm-0-0-8239],[@b59-etm-0-0-8239]). Certain studies indicated no beneficial effect of autologous EPC transplantation in diabetic patients with critical limb ischemia ([@b58-etm-0-0-8239]). The controversy may be attributed to the heterogeneity of survival and different sources of EPCs in these trials ([@b7-etm-0-0-8239],[@b58-etm-0-0-8239]). The present results revealed that inflammatory responses and associated genes may be partially involved in the abnormal function and number of EPCs in patients with diabetes.

Taken together, the present study identified DEGs in the EPCs of patients with type 2 DM vs. healthy subjects, which may be involved in the changes in the number and function of EPCs in patients with type 2 DM. Hub genes (IL8, FPR1, CXCL1, GNAI3, FPR2, GNAI2, ANXA1, GNB1 and LPAR5) extracted from the PPI network may be helpful as potential diagnostic and prognostic biomarkers of disordered EPCs. In addition, inflammatory responses are critical for the reduced number and hypofunction of EPCs isolated from diabetic patients.

The present study has several limitations that should be pointed out. First, it was not possible to conclude whether changes in gene expression were the cause or consequence of the complex physiological environment in patients with type 2 DM. Furthermore, the sample size of EPCs was relatively small (n=4 for each group). Third, due to the lack of a sorting machine, the EPCs in the present study were isolated and cultured in culture dishes. EPCs isolated from the patients in Sir Run Run Shaw Hospital were cultured *in vitro* while CD34^+^ cells were directly sorted in GSE43950. Therefore, the fold changes of identified hub genes may not fit well with the predicted outcomes of microarrays in GSE43950. Finally, as the clinical traits in the dataset GSE43950 were limited, the exact clinical characteristics of these patients were not known. In the current, the probes were annotated using the platform annotation file, which was last updated in July 09, 2014 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL10379>). Therefore, some proteins discovered in the past few years may not be identified in the present study.
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![The volcano plot and heatmap of differentially expressed genes in type 2 DM. (A) Volcano plot of DEGs. The x-axis represents the log2 FC and the y-axis represents the log10 (P-value). The green dots represent downregulated genes and red dots represent upregulated genes. (B) Heat map of DEGs following clustering analysis. The vertical axis represents the sample, and the horizontal axis represents DEGs. Red indicates upregulated and blue represents downregulated genes. (C) DEGs were selected according to P\<0.05 and \|log2 FC\|≥1. DEGs, differentially expressed genes; DM, diabetes mellitus; CTRL, control; FC, fold change.](etm-19-01-0499-g00){#f1-etm-0-0-8239}

![GO and KEGG enrichment analyses of DEGs. (A-C) Scatterplots of the top 10 enriched (A) BP, (B) CC and (C) MF terms for the DEGs. (D) The top 10 KEGG pathways for the DEGs. The size and color of the dots represent the gene number and the range of P-values, respectively. DEGs, differentially expressed genes; GO, Gene Ontology; BP, Biological Process; CC, Cellular Component; MF, Molecular Function; KEGG, Kyoto Encyclopedia of Genes and Genomes.](etm-19-01-0499-g01){#f2-etm-0-0-8239}

![Protein-protein interaction network of differentially expressed genes. Proteins with degrees ≥20 were visualized in detail. Circles with green and red margins represent the downregulated and upregulated genes, respectively. Lines indicate protein-protein interactions.](etm-19-01-0499-g02){#f3-etm-0-0-8239}

![Results of the subnet analysis of the PPI network. Three modules, (A) Module a, (B) module b and (C) module c were extracted from the PPI network in Cytoscape using the MCODE plugin. Circles with green and red margins represent the downregulated and upregulated genes, respectively. Lines indicate PPIs. PPI, protein-protein interaction.](etm-19-01-0499-g03){#f4-etm-0-0-8239}

![Obtainment of 9 hub genes, construction of PPI network and enrichment analysis of hub genes. (A) Overlapping DEGs among the three topological cytoHubba methods including, maximal clique centrality, maximum neighborhood component and density of maximum neighborhood component. (B) PPI interaction network of DEGs determined by STRING and visualized in Cytoscape. Lines indicate protein-protein interactions. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PPI, protein-protein interaction; DEG, differentially expressed gene.](etm-19-01-0499-g04){#f5-etm-0-0-8239}

![Validation of microarray data by quantitative PCR. The expression of the top 9 hub genes identified from the microarray in detected in endothelial progenitor cells from patients with DM and healthy controls is provided in bar graphs. (A) IL8, (B) FPR1, (C) CXCL1, (D) GNAI3, (E) FPR2, (F) GNAI2, (G) ANXA1, (H) GNB1, (I) LPAR5. Values are expressed as the mean ± standard deviation (n=4 in each experiment). \*P\<0.05, \*\*P\<0.01 vs. control group. DM, diabetes mellitus; C, control; IL8, interleukin 8; FPR1, formyl peptide receptor 1; CXCL1, C-X-C motif chemokine ligand 1; GNAI3, G protein subunit alpha I3; FPR2, formyl peptide receptor 2; GNAI2, G protein subunit alpha 2; ANXA1, annexin A1; GNB1, G protein subunit beta 1; LPAR5, lysophosphatidic acid receptor 5.](etm-19-01-0499-g05){#f6-etm-0-0-8239}

![Appropriate soft-threshold power selection and construction of the cluster dendrogram. (A) Analysis of the scale-free fit index for various soft-threshold powers. (B) Analysis of the mean connectivity for various soft-threshold powers. (C) The co-expression modules constructed by weighted gene co-expression network analysis and visualized in the cluster dendrogram. Each colored row represents a color-coded module that contains a group of highly connected genes.](etm-19-01-0499-g06){#f7-etm-0-0-8239}

![Network analysis of gene expression in type 2 DM and investigation of the module containing IL8 and CXCL1. (A) Module-trait associations. Each row corresponds to an ME, containing the corresponding correlation and P-value. The column represents the clinical trait of type 2 DM. The table was colored according to the correlation between ME and clinical traits. (B) The MM vs. GS plot for the pink module indicated that MM and GS are highly correlated. (C) Scatterplot of enriched Kyoto Encyclopedia of Genes and Genomes pathways for the pink module. The size and color of the dots represent the gene number and the range of P-values, respectively. ME, module eigengene; GS, gene significance; DM, diabetes mellitus; MM, module membership; IL8, interleukin 8; CXCL1, CXC motif chemokine ligand 1.](etm-19-01-0499-g07){#f8-etm-0-0-8239}

###### 

Primers used for quantitative PCR.

          Primer sequence (5′→3′)   
  ------- ------------------------- -------------------------
  IL8     TTTTGCCAAGGAGTGCTAAAGA    AACCCTCTGCACCCAGTTTTC
  FPR1    AAGGCCATGGGAGGACATTG      CAGGGCCCAATGATCACCTT
  CXCL1   CTGGCGGATCCAAGCAAATG      GCCCCTTTGTTCTAAGCCAG
  GNAI3   ATCGACCGCAACTTACGGG       AGTCAATCTTTAGCCGTCCCA
  FPR2    CTGAATGGATCAGAAGTGGTGG    CCCAAATCACTAGTCCATTGCC
  GNAI2   TACCGGGCGGTTGTCTACA       GGGTCGGCAAAGTCGATCTG
  ANXA1   GCGGTGAGCCCCTATCCTA       TGATGGTTGCTTCATCCACAC
  GNB1    GTGAGCTTGACCAGTTACGG      TGTGATCTGAGAGAGAGTTGCAT
  LPAR5   CGCCATCTTCCAGATGAAC       TAGCGGTCCACGTTGATG
  GAPDH   CCTGCACCACCAACTGCTTA      GGCCATCCACAGTCTTCTGAG

###### 

Top 10 up- and downregulated differentially expressed genes.

  A, Upregulated genes                                                        
  ---------------------------- ------------------------------ --------------- --------------
  NLRP3                        7.94243                        3.05234         2.44×10^−10^
  NINJ1                        8.64930                        2.94253         2.39×10^−9^
  G0S2                         9.91064                        6.10854         1.88×10^−8^
  CKAP4                        6.42605                        2.65448         8.77×10^−8^
  MAFB                         9.35177                        3.80994         1.78×10^−7^
  C20orf24                     9.77482                        1.48972         2.72×10^−7^
  C5AR1                        7.62619                        4.01330         3.48×10^−7^
  PTX3                         6.21338                        3.11387         3.64×10^−7^
  PFKFB3                       8.33607                        2.69583         4.12×10^−7^
  ID2                          10.66494                       1.77079         5.55×10^−7^
                                                                              
  **B, Downregulated genes**                                                  
                                                                              
  **Gene**                     **Average expression value**   **Log~2~ FC**   **P-value**
                                                                              
  TRUB2                        4.16713                        −1.14507        8.59×10^−7^
  PKIA                         5.22172                        −1.33779        3.09×10^−5^
  GPATCH4                      7.44535                        −1.25382        3.87×10^−5^
  EIF5B                        8.92228                        −1.07249        4.75×10^−5^
  CNNM3                        6.16580                        −1.40637        1.23×10^−4^
  CD72                         3.27212                        −1.55625        1.30×10^−4^
  ZDHHC14                      5.93256                        −1.11224        1.68×10^−4^
  ENO2                         4.21881                        −1.58752        1.72×10^−4^
  PPM1K                        3.60385                        −1.38364        2.05×10^−4^
  DAZAP1                       9.80455                        −1.03973        2.29×10^−4^

FC, fold change.

###### 

Information on the 9 hub genes.

  Gene    Log~2~ FC   P-value       Degree   Expression alteration
  ------- ----------- ------------- -------- -----------------------
  IL8     3.89158     9.02×10^−6^   43       Upregulated
  FPR1    3.04300     4.82×10^−5^   22       Upregulated
  CXCL1   2.49797     3.30×10^−4^   22       Upregulated
  GNAI3   2.09317     1.38×10^−3^   24       Upregulated
  FPR2    2.83408     2.84×10^−3^   26       Upregulated
  GNAI2   1.01805     3.26×10^−3^   22       Upregulated
  ANXA1   2.18436     4.56×10^−3^   26       Upregulated
  GNB1    1.12879     1.48×10^−2^   33       Upregulated
  LPAR5   −1.20699    2.81×10^−2^   25       Downregulated

FC, fold change; IL8, interleukin 8; FPR1, formyl peptide receptor 1; CXCL1, C-X-C motif chemokine ligand 1; GNAI3, G protein subunit alpha I3; FPR2, formyl peptide receptor 2; GNAI2, G protein subunit alpha 2; ANXA1, annexin A1; GNB1, G protein subunit beta 1; LPAR5, lysophosphatidic acid receptor 5.
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